Stephen Tang to Leave OraSure Technologies, Inc. as CEO, Effective March 31, 2022
January 05, 2022 at 07:05 am EST
Share
OraSure Technologies, Inc. announced that Stephen Tang Ph.D., President and CEO, will be the leaving the Company as of March 31, 2022. In the interim, Dr. Tang will focus primarily on assisting the Board in its strategic review process and helping to ensure an orderly transition of the CEO role. The Board has initiated a search for his successor as CEO. During this transition, while the CEO search is in
process, the Board of Directors will be taking a more active role. For this purpose, the Board has appointed
Director Eamonn Hobbs to serve as point person for the Board. Mr. Hobbs will not be a candidate for the
permanent CEO position.
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
ORASURE TECHNOLOGIES, INC. 
